Clinical trials: Residual
Type I Hypersensitivity
Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing
The purpose of this study is to evaluate the residual allergenicity of Grass MATA (modified pollen allergen tyrosine adsorbate) by skin prick testing.
- Trial name
- NCT00104390
- Testing
- Grass MATA MPL
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Allergy Therapeutics
Amputation, Amputation; Traumatic, Leg, Lower
Socket Cooling Effectiveness Take Home Study
The comfort and fit of the residual limb within a prosthetic socket are of primary concern for many amputees. The residual limb is typically covered by non-breathable and non- thermally conductive materials that can create a warm…
- Conditions
- Amputation, Amputation; Traumatic, Leg, Lower, Amputation Stump, Limb; Absence, Congenital, Lower
- Trial name
- NCT04484805
- Testing
- ICE Condition
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Liberating Technologies, Inc.
Leukemia, Myeloid, Acute
HDM201 Added to CT in R/R or Newly Diagnosed AML
This is a multi-center open-label Phase I/II study investigating orally administered HDM201 in combination with chemotherapy in two populations: subjects with first line AML or subjects with relapsed/refractory AML.
- Trial name
- NCT03760445
- Testing
- HDM201, cytarabine, anthracycline
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like…
- Trial name
- NCT04634435
- Testing
- BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations
This study is a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial evaluating the efficacy and safety of HMPL-306 in participants with postoperative residual or recurrent grade 2 gliomas carrying…
- Trial name
- NCT07912398
- Testing
- HMPL-306 tablet
- Volunteers
- 210 people
- Sponsor
- Hutchmed
B Cell Precursor Acute Lymphoblastic Leukemia
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL), to…
- Trial name
- NCT04521231
- Testing
- Blinatumomab
- Where
- 109 sites in United States, Argentina and 18 more
- Volunteers
- 181 people
- Sponsor
- Amgen
Peripheral Arterial Disease
BIO REsponse Adapted Combination Therapy Pilot Study
Both drug-coated balloon and stents have been used for a number of years to treat subjects with Peripheral Artery Disease (PAD) and are recognized as very good treatment methods.
- Trial name
- NCT03547986
- Testing
- Duplex Ultrasound (DUS), IVUS with Intraarterial pressure measurement (IAP) if needed
- Where
- 15 sites in Australia, Austria and 4 more
- Volunteers
- 150 people
- Sponsor
- Biotronik AG
Type 1 Diabetes Mellitus
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd also known as retogatein compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous…
- Trial name
- DIAGNODE-3 (NCT05018585)
- Testing
- Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU
- Where
- 60 sites in United States, Czechia and 7 more
- Volunteers
- 321 people
- Sponsor
- Diamyd Medical AB
Chronic Renal Failure
Initiative for Patient Outcomes in Dialysis - Peritoneal Dialysis (PD) (IPOD-PD Study)
The aim of the study is to asses the hydration status of incident peritoneal dialysis (PD) patients and its evolution over a period of four years, independent of the PD treatment modality (APD or CAPD) and the PD solution type.
- Trial name
- IPOD-PD (NCT01285726)
- Testing
- Non-interventional study
- Where
- 134 sites in Austria, Belgium and 26 more
- Volunteers
- 1,092 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Respiratory Viral Illnesses: Influenza A/B, RSV, Adenovirus
Residual Sample Collection for Respiratory Viral Panel
Collect de-identified, residual samples to support a clinical trial. Samples may be prospectively or retrospectively collected. Overall Study Objective Obtain clinical performance data to characterize clinical performance of the…
- Trial name
- NCT02049918
- Where
- United States
- Volunteers
- 1,487 people
- Sponsor
- GenMark Diagnostics
Healthy
Evaluation of Residual Urine After Intermittent Catheterisation
Intermittent catheterization is a well-known method used for emptying the bladder. The objective of this study is to compare the residual urine after intermittent catheterisation with 2 different, hydrophilic coated, intermittent…
- Trial name
- NCT00324233
- Testing
- Intermittent catheter, Compact intermittent catheter
- Where
- Denmark
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Coloplast A/S
Multiple Myeloma, Neoplasm, Plasma Cell
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT).
- Conditions
- Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms
- Trial name
- NCT04309084
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Celularity Incorporated
Non-Hodgkin's Lymphoma
A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's Lymphoma
This single-arm, open-label, multi-centre study will evaluate the efficacy and safety of MabThera/Rituxan (rituximab) in patients with follicular non-Hodgkin's lymphoma with minimal residual disease after autologous…
- Trial name
- NCT01388959
- Testing
- rituximab [MabThera/Rituxan]
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Observation of Neuromuscular Block
Residual Curarization and Its Incidence at Tracheal Extubation (P08194)
This study will assess the residual neuromuscular blockade (NMB) Train-Of-Four (TOF) ratios at tracheal extubation when anesthesiologists have determined that full recovery of neuromuscular function has occurred using standard…
- Trial name
- RECITE (NCT01318382)
- Testing
- TOF-Watch SX® Monitoring of NMB
- Volunteers
- 302 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Neoplasms
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery
The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of residual colorectal cancer following recent surgery.
- Trial name
- NCT00041691
- Testing
- hMN14 (labetuzumab)
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Neuropathic Pain, Phantom Limb Pain
Clinical Evaluation of the Medical Device (MD) (Caloprothese Connected Kit, CCK)
Neuropathic pain is common in limb amputees and causes reductions in activity and participation as well as impaired quality of life.
- Trial name
- KCC (NCT04748484)
- Testing
- KCC Active or inactive
- Where
- 4 sites in France
- Volunteers
- 12 people
- Sponsor
- Gregand Innovations
Colorectal Cancer
First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer
The CORRECT - MRD I study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for up to 5 years for recurrence.
- Trial name
- MRD (NCT06398743)
- Testing
- MRD
- Where
- 22 sites in Israel, Italy and 3 more
- Volunteers
- 416 people
- Sponsor
- Exact Sciences Corporation
CML (Chronic Myelogenous Leukemia)
Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment
The main purpose of the trial is to evaluate the safety and potential side effects of cell therapy vididencel in Chronic Myeloid Leukemia (CML) participants with measurable residual disease (MRD) unable to stop treatment with…
- Trial name
- NCT07651878
- Testing
- vididencel
- Where
- Norway
- Volunteers
- 24 people
- Sponsor
- Mendus
Hepatitis C
A Registration Study to Evaluate the Performance of CHIRON® RIBA® HCV 3.0 SIA in HCV Antibody Detection
To evaluate the accuracy of the CHIRON® RIBA® HCV 3.0 (RIBA, Investigational Product) test using known anti-HCV seropositive and seronegative specimens. Registration for license application
- Trial name
- NCT01582594
- Where
- 4 sites in China
- Volunteers
- 795 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Medical, China
Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia
The clonoSEQ® Watch Registry
This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL).
- Conditions
- Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma
- Trial name
- NCT04545333
- Testing
- clonoSEQ Assay
- Where
- 14 sites in United States
- Volunteers
- 465 people
- Sponsor
- Adaptive Biotechnologies